Benefits
Cardiovascular protection
Reduces LDL oxidation, inhibits platelet aggregation, improves endothelial function, and modestly lowers blood pressure. The older "French Paradox" narrative attributing this to red wine is now largely discounted, since wine contains only trace resveratrol far below the doses used in trials.
Sirtuin pathway (investigational)
In preclinical models resveratrol has been proposed to activate SIRT1 and mimic aspects of caloric-restriction signaling, but the original direct-activation finding was later attributed to an artifact of the assay used, and caloric-restriction-mimetic or longevity benefits have not been demonstrated in humans. Any effect on mitochondrial biogenesis or stress-resistance pathways in people remains unproven.
Anti-inflammatory effects
Inhibits NF-κB transcription factor, reducing production of inflammatory cytokines (TNF-α, IL-6, IL-1β) and COX enzymes. Clinically shows reduced CRP levels in metabolic syndrome patients.
Blood sugar regulation
May improve insulin sensitivity (proposed via AMPK, with a contested SIRT1 contribution) and reduce postprandial glucose spikes. RCTs in type 2 diabetes show modest improvements in HbA1c and fasting glucose.
Postmenopausal pain, vasomotor symptoms, and bone metabolism
The 24-month RESHAW trial (Resveratrol Supporting Healthy Aging in Women) — the longest resveratrol study to date — demonstrated that 75 mg twice daily in 125 postmenopausal women produced significant reductions in pain perception, vasomotor symptoms (hot flushes, night sweats), somatic symptoms (joint and muscle discomfort), sleep disturbance, and improved overall quality of life. A recent systematic review reported improvements in pain scores and a bone-resorption marker (CTX), though effects on general menopausal symptoms varied across studies. Mechanism is partly via estrogen receptor binding (resveratrol acts as a phytoestrogen) and improved cerebrovascular function.
Mechanism of action
SIRT1 deacetylase activation
Resveratrol has been proposed to activate SIRT1 (a contested mechanism — the original allosteric direct-activation finding was later shown to be largely an artifact of the fluorophore-tagged substrate assay, and much of any real effect may be indirect via AMPK). Where SIRT1 is engaged it can promote deacetylation of PGC-1α, FOXO transcription factors, and p53.
AMPK pathway stimulation
Resveratrol inhibits mitochondrial ATP synthase at low concentrations, transiently raising AMP:ATP ratio and activating AMPK — improving glucose uptake, fatty acid oxidation, and mitochondrial function.
Estrogenic activity
Resveratrol is a phytoestrogen that binds estrogen receptors (ERα and ERβ) with preferential affinity for ERβ, producing tissue-selective estrogenic effects relevant to bone, brain, and cardiovascular tissue.
Clinical trials
Clinical trial of 150 mg/day resveratrol vs placebo in 11 obese but healthy men over 30 days. Outcomes: energy expenditure, mitochondrial function, HOMA-IR, lipids. (Timmers et al. 2011, Cell Metab, PMID 22055504)
11 obese healthy men (very small).
Resveratrol modestly affected metabolic parameters — reduced sleeping metabolic rate, improved mitochondrial function, lowered HOMA-IR, reduced triglycerides and inflammatory markers. Critical caveat: very small trial (n=11); the dramatic 'caloric restriction mimetic' framing rests on limited human data. Subsequent larger trials have been mixed.
Evidence review and pooled analysis of 11 clinical trials examining resveratrol in T2DM patients. (pooled analysis of published RCTs)
Pooled across 11 T2DM clinical trials.
Modest reductions in fasting glucose, HbA1c, insulin resistance, systolic BP. Effect sizes modest. Note: T2DM management uses metformin, GLP-1 agonists, SGLT-2 inhibitors as evidence-based first-line — resveratrol adjunctive at most.
24-month, randomized, double-blind, placebo-controlled, two-period crossover trial (RESHAW) of resveratrol (75 mg twice daily, 150 mg/day) vs placebo in postmenopausal women. Outcomes: pain, vasomotor symptoms, cognition, BMD. (Thaung Zaw et al. 2020, Menopause, PMID 32881835; bone-density arm Wong et al. 2020, J Bone Miner Res, PMID 32564438)
Postmenopausal women. 24-month long-term.
Resveratrol modestly improved pain perception, vasomotor symptoms (hot flushes), and cognitive measures vs placebo. Notable long-term trial — most resveratrol research is shorter. Modest effects.